Artrilom® 7.5 mg, 15 mg /Note: In many countries the product is available under the trademark “LORMED®”/
tablets
![ArtrilomRR 7.5 mg, 15 mg /Note: In many countries the product is available under the trademark “LORMEDRR”/](javascript:obrazek_big("http://promedcs.cz//en/../img/baleni/600_Artrilom_5,15_web(5).jpg", "en"); "ArtrilomRR 7.5 mg, 15 mg /Note: In many countries the product is available under the trademark “LORMEDRR”/")
- Manufacturer:
- Chanelle Medical Ltd., Loughrea, Ireland.
- Marketing authorisation holder:
- PRO.MED.CS Praha a.s.
- Composition:
- Meloxicamum 7.5 mg or 15 mg in one tablet.
- Indication group:
- antirheumatic agent, antiphlogistic agent
The following information is for health professionals only.
READ CAREFULLY THIS NOTICE!
Characteristics:
It is an oxicam nonsteroidal antirheumatic drug (NSAID) with good analgesic and anti-inflammatory effects. It is a partially selective inhibitor of cyclooxygenase 2 (COX 2), which inhibits the synthesis of prostaglandins (mediators of inflammation) and reduces particularly gastrointestinal and renal undesirable effects. Biological availability after peroral administration is 89%, the maximal plasma concentrations are achieved in 5-6 hours. It is excreted partly in the urine and partly in the bile in the form of metabolites. The biological half-life of elimination is 15-20 hours. Anti-inflammatory effects develop in 1-2 weeks, analgesic effects after peroral administration after 90 minutes.
Indications:
Short-term symptomatic treatment of exacerbations of osteoarthrosis. Long-term symptomatic treatment of rheumatoid arthritis or ankylosing spondylitis.
Contraindications:
Hypersensitivity to meloxicam, auxiliary substances, other NSAIDs, active gastrointestinal ulcer or relapsing gastrointestinal ulcer, gastrointestinal bleeding, serious deterioration of hepatic functions, nondialyzed serious renal failure, cerebrovascular bleeding and other haemorrhagic conditions, serious heart failure congestive, the third trimester of gravidity, breast-feeding, and administration to children younger than 15 years. Meloxicam must not be administered to patients who, after previous administration of ASA or other drugs of the NSAID group, developed asthma, nasal polyps, angioedema or urticaria.
Undesirable effects:
Gastrointestinal troubles, rarely gastrointestinal ulceration, headaches, pruritus, allergic skin reactions, photosensitivity, anaemia, hepatic or renal function disorders, and retention of fluids accompanied by swellings.
Interactions:
Meloxicam increases plasma levels of lithium and methotrexate, increases cyclosporin nephrotoxicity, enhances the effects of peroral anticoagulant agents and antiaggregant agents, and decreases the effect of diuretics. Meloxicam may decrease the effect of some antihypertensive agents (β-blockers, ACE-inhibitors). In combination with other NSAIDs and glucocorticoids it increases the risk of gastrointestinal ulcers and bleeding.
Caution:
Meloxicam may produce dizziness, drowsiness or vision disorders and thus influence driving and operation of machines.
Dosage:
Exacerbation of osteoarthrosis: 7.5-15 mg once a day. Rheumatoid arthritis, ankylosing spondylitis: 15 mg once a day. The daily dose of 15 mg should not be exceeded. The total daily dose is administered as a single dose with meals and washed down with water.
Package:
20 tablets of 7.5 mg;
10, 20, 50 tablets of 15 mg.
For greater details about the preparation see the product data summary.
Date of the latest revision of the text: November 28, 2007.
The preparation is available on medical prescription only.